Clinical trial register · Spain

Clinical Trials in Pamplona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Pamplona

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Not yet open

Analysis of the Role of the Microbiota in Diverticular Disease

NCT07681505Diverticular Disease of Colon, Acute Diverticulitis, Gut Microbiota

Hospital of Navarra

Observational

285

Pamplona

2027-06-01

Not yet open

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188Relapsed or Refractory Multiple Myeloma

DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide

AbbVie

Phase 3

520

Santander, Pamplona, Madrid

2026-11-30

Not yet open

A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer

NCT07711067Pancreatic Ductal Adenocarcinoma (mPDAC), Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

ElmediX

Phase 2/3

Madrid, Pamplona

2026-10-01

Not yet open

Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)

NCT07788664Advanced Gastric Cancer

DrugsRilvegostomig·Keytruda·Pembrolizumab

Vall d'Hebron Institute of Oncology

Phase 2

Barcelona, Madrid, Pamplona

2026-10-01

Recruiting

Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis

NCT07799116Lupus Nephritis, Lupus Nephritis (LN)

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Phase 1/2

Badalona, Santiago de Compostela, Pamplona, León, Madrid, Murcia, Salamanca, Seville

2026-09-23

Recruiting

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

NCT07701941Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer

DrugsPatritumab deruxtecan·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 1/2

220

Badalona, Barcelona, Granada, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santa Cruz de Tenerife

2026-09-17

Not yet open

Acute Effects of Active Breaks and Physically Active Learning in University Students

NCT07809750Cognitive Performance, Academic Performance

Universidad Complutense de Madrid

Not applicable

700

Pamplona

2026-09-15

Not yet open

Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae

NCT07396571Hemato-oncologic Patients, Colonization, Neutropenia, Enterobacteria Non Susceptible to Carbapenem Carrier

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Observational

535

Almería, Jerez de la Frontera, Vigo, Pamplona, Barcelona, Cadiz, Granada, Huelva

2026-09-04

Recruiting

Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer

NCT07805252Advanced Solid Tumors Cancer

Orion Corporation, Orion Pharma

Phase 1/2

195

Logroño, Madrid, Barcelona, Pamplona

2026-09-03

Recruiting

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

NCT07192471T-cell NHL (PTCL or CTCL)

Kyowa Kirin, Inc.

Phase 1

Badalona, L'Hospitalet de Llobregat, Pamplona, Madrid

2026-09-02

Not yet open

Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma

NCT07763171Gastroesophageal Adenocarcinoma

DrugsRamucirumab·Folfox·Tislelizumab·Paclitaxel

Gruppo Oncologico del Nord-Ovest

Phase 3

244

Barcelona, Madrid, Málaga, Ourense, Pamplona, Santander, Valencia, Zaragoza

2026-09-01

By invitation

BIOANCIENT_EX: Effects of a Physical Exercise Program in Centenarians of the BIOANCIENT Cohort: A Randomized Clinical Trial.

NCT07723339Aging, Cellular Senescence, Biomarkers / Blood, Exercise

Fundacion Miguel Servet

Not applicable

Pamplona

2026-08-13

Recruiting

Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)

NCT07864207Small Cell Lung Cancer ( SCLC )

DrugIDP-121

IDP Discovery Pharma S.L.

Phase 1/2

Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia

2026-07-28

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Badalona, Barcelona, Madrid, Málaga, Pamplona, Santander, Seville, Valencia

2026-07-10

Recruiting

Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation

NCT07575269Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation

Boston Scientific Corporation

Not applicable

571

Pamplona

2026-07-07

Not yet open

Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care

NCT07678372Wound Healing, Abdominal Surgery, Scar Improvement

Laboratorios Ozoaqua

Not applicable

144

Pamplona

2026-07-06

Recruiting

Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors

NCT07215364Early-stage Breast Cancer

Spanish Breast Cancer Research Group

Not applicable

L'Hospitalet de Llobregat, Pamplona, Granada, Madrid, Seville

2026-07-02

Not yet open

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

NCT07507968Esophagogastric Adenocarcinoma

DrugDurvalumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

101

Badalona, Barcelona, Granada, Jaén, Málaga, Oviedo, Pamplona, Valencia

2026-07-01

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

NCT07581002Acute Myeloid Leukemia

DrugsPivekimab Sunirine·Azacitidine·Venetoclax

AbbVie

Phase 2/3

660

Majadahonda, Pamplona, Seville, Madrid, Valencia

2026-06-30

Recruiting

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

NCT07589634Multiple Myeloma

DrugsRamantamig·Tocilizumab

Janssen Research & Development, LLC

Phase 2

230

Madrid, Pamplona, Valencia

2026-06-30

Recruiting

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

NCT07764978Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab

AstraZeneca

Phase 3

750

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2026-06-26

Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

NCT07555938Multiple Myeloma

DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide

Hoffmann-La Roche

Phase 3

380

Marbella, Pamplona, Barcelona, Madrid, Salamanca

2026-06-23

Active, closed

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugsCliramitug·Eplontersen

AstraZeneca

Phase 2

326

Barcelona, Jaén, L'Hospitalet de Llobregat, Majadahonda, Málaga, Pamplona, Salamanca, Valencia

2026-06-11

Recruiting

VIVI-OLIVE: Multicomponent Exercise and Extra Virgin Olive Oil in Older Adults at High Risk of Falls

NCT07829484Falls, Frailty

Fundacion Miguel Servet

Not applicable

140

Pamplona

2026-06-10

Active, closed

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation

DrugsTNO155·Opnurasib·Trametinib·Cetuximab

Novartis Pharmaceuticals

Phase 1/2

Pamplona, Barcelona, Madrid, Valencia

2026-06-08

Recruiting

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma

Blueprint Medicines Corporation

Phase 1/2

265

Barcelona, Madrid, Pozuelo de Alarcón, Pamplona

2026-06-04

Recruiting

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934Metastatic Prostate Cancer

DrugsAZD2287·FPI-2265·Palacaparib·Docetaxel

AstraZeneca

Phase 1/2

152

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona

2026-06-03

Not yet open

Masitinib in Patients With Mild Alzheimer's Disease

NCT05564169Alzheimer Disease

DrugMasitinib

AB Science

Phase 3

600

Albacete, Barcelona, Donostia / San Sebastian, Granada, Madrid, Murcia, Pamplona, Zamora

2026-06

Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

700

Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Salamanca, Santander

2026-05-31

Recruiting

Exploration of Potential Biomarkers of Polyphenol Intake From Artichoke By-product Supplements

NCT07615673Healthy Adult Participants, ADME, Polyphenols Absorption Profile, Polyphenolic Compounds and Metabolism

Iziar Amaia Ludwig Sanz Orrio

Not applicable

Pamplona

2026-05-26

Recruiting

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

NCT07479797Relapsed or Refractory Large B-cell Lymphoma

DrugsKITE-753·Axicabtagene Ciloleucel·Fludarabine·Cyclophosphamide

Kite, A Gilead Company

Phase 3

550

Barcelona, Madrid, Pamplona, Salamanca

2026-05-22

Recruiting

Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies

NCT07644039Advanced Malignancies

DrugsPM54·Pembrolizumab

PharmaMar

Phase 1/2

119

Barcelona, Madrid, Pamplona

2026-05-21

Recruiting

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

NCT07572006Hematologic Neoplasms

Janssen Research & Development, LLC

Phase 1

360

Madrid, Pamplona

2026-05-13

Recruiting

Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors

NCT07424092High Grade Glioma, Ependymoma, Embryonal Tumor of Brain, Recurrence

DrugDNX-2401

Clinica Universidad de Navarra, Universidad de Navarra

Phase 2

Pamplona

2026-05-12

Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031Solid Tumors

DrugsAdagrasib·Fluorouracil·Leucovorin·Irinotecan

Mirati Therapeutics Inc.

Phase 2

170

A Coruña, Palma, Barcelona, Badalona, Santander, Madrid, Pamplona, Valencia

2026-05-06

Recruiting

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

NCT07607678Advanced Solid Cancer, Metastatic Solid Cancer

DrugEzabenlimab

Boehringer Ingelheim

Phase 1

Barcelona, Pamplona, Valencia

2026-05-01

Recruiting

Artichoke By-products Rich in Hydroxycinnamic Acids and Mediterranean Diet for Type 2 Diabetes Prevention.

NCT07415720Diabete Type 2, Obesity & Overweight, Insulin Resistance Syndrome

Clinica Universidad de Navarra, Universidad de Navarra

Not applicable

150

Pamplona

2026-05

Recruiting

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06769698Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugCemiplimab

Regeneron Pharmaceuticals

Phase 2

120

Seville, Barcelona, A Coruña, Pamplona, Madrid, Zaragoza

2026-04-14

Recruiting

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

NCT07387068Advanced Solid Tumors

Genmab

Phase 1

121

Logroño, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid

2026-04-07

Not yet open

Extended Versus Short Prehabilitation Programme for Patients With Advanced Ovarian Cancer Undergoing Major Surgery

NCT07509814Ovarian Cancer With Peritoneal Carcinosis

Hospital Clinic of Barcelona

Not applicable

225

Badalona, Barcelona, Madrid, Pamplona, Valencia

2026-04-01

Not yet open

Study of Functional Decline and Care Pathways in Neurosurgical Patients Over 65 Years of Age

NCT07506941Ageing and Geriatric Health

University Hospital, Toulouse

Observational

209

Alicante, Ourense, Pamplona

2026-04-01

Recruiting

Concomitant Use of Radiotherapy and Integrated Exercise - Lung Cancer

NCT07489391Non Small Cell Lung Cancer, Radiation Therapy Patient, Stage II/III

University of Deusto

Not applicable

Barcelona, Pamplona

2026-04

Recruiting

Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration

NCT07523620Atrial Fibrillation (AF), Paroxysmal AF, Persistent Atrial Fibrillation

Abbott Medical Devices

Not applicable

240

Barcelona, Pamplona

2026-03-31

Recruiting

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

NCT07146906Immunoglobulin A Nephropathy (IgAN)

DrugZigakibart

Novartis Pharmaceuticals

Phase 2

Pamplona, Valencia, Barcelona, Seville

2026-03-26

Recruiting

Beetroot Extract and Quality of Life in Adults Aged 75 and Over

NCT07666685Cardiovascular Health, Functional Health, Cognitive Function Decline, Physical Performance Decline in Older Adults

Fundacion Miguel Servet

Not applicable

120

Pamplona

2026-03-24

Recruiting

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

DrugsVisugromab RDE·Opdivo·Lenvatinib·Nivolumab

CatalYm GmbH

Phase 2

104

Zaragoza, L'Hospitalet de Llobregat, Barcelona, Pamplona, Madrid

2026-03-19

Recruiting

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

NCT07387367Adenovirus Infections

SymBio Pharmaceuticals

Phase 3

180

Barcelona, Madrid, Pamplona, Salamanca

2026-03-17

Recruiting

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076Hepatocellular Carcinoma (HCC)

DrugsPumitamig·Yervoy·Ipilimumab

Bristol-Myers Squibb

Phase 1/2

198

Pamplona, Barcelona, Madrid

2026-03-16

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045Obesity or Overweight

Hoffmann-La Roche

Phase 3

2,000

Santander, A Coruña, Pamplona, Barcelona, Madrid, Seville, Valencia

2026-03-16

By invitation

FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors

NCT07181135Chronic Kidney Disease

DrugFinerenone

University Medical Center Groningen

Phase 3

180

Barcelona, Madrid, Pamplona, Valencia

2026-03-13

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

DrugsPumitamig·Folfox·Nivolumab

Bristol-Myers Squibb

Phase 2/3

690

Barcelona, Santander, Pamplona, Valencia, Madrid, Málaga

2026-03-13

Recruiting

Study on Prostate Salvage Using High-dose-rate Brachytherapy

NCT07860528Prostate Cancer, Locally Recurrent Cancer, Biochemically Recurrent Prostate Carcinoma, Toxicity Radiation

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Observational

Benidorm, L'Hospitalet de Llobregat, Santander, Córdoba, San Sebastián, Madrid, Pamplona, Vigo

2026-03-11

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Badalona, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Palma de Mallorca, Pamplona, Pozuelo de Alarcón

2026-03-05

Recruiting

Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome

NCT07476859Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)

DrugsFerinject·Ferric Carboxymaltose

Fundación para la Investigación del Hospital Clínico de Valencia

Phase 4

538

El Palmar, Vigo, Badajoz, Barcelona, Granada, León, Madrid, Pamplona

2026-03-05

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Barcelona, Huelva, Madrid, Pamplona, Santander, Santiago de Compostela, Seville, Valladolid

2026-03-05

Recruiting

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398Pulmonary Hypertension Associated With HFpEF

DrugTNX-103

Tenax Therapeutics, Inc.

Phase 3

540

Barcelona, Lugo, Madrid, Marbella, Málaga, Pamplona, Salamanca, Seville

2026-03-03

Not yet open

Application of Indocyanine Green Tracer in D2 Lymphadenectomy of Locally Advanced Gastric Cancer

NCT06892392GASTRIC CANCER, Indocyanine Green (ICG), Lymph Node Excision, Lymphadenectomy

Hospital of Navarra

Not applicable

102

Pamplona

2026-03-01

Recruiting

LONG NAGOMI™ PMCF STUDY

NCT07399002Coronary Artery Disease, Ischemic Heart Disease

Fundación EPIC

Observational

1,039

Cabueñes, Ciudad Real, Elche, Huelva, León, Málaga, Pamplona, Santander

2026-02-27

Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657Relapsed Refractory Multiple Myeloma

DrugsAZD0120·Darzalex·Velcade·Carfilzomib

AstraZeneca

Phase 3

508

Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia

2026-02-23

Recruiting

A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

NCT07250750Myasthenia Gravis

ImmunAbs Inc.

Phase 1/2

Madrid, Pamplona

2026-02-05

Recruiting

BIOANCIENT: Cohort of Centenarians in Navarra (1926-1927)

NCT07707297Aging, Cellular Senescence, Biomarkers / Blood, Age-Related Diseases

Fundacion Miguel Servet

Observational

333

Pamplona

2026-02-04

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Barcelona, Madrid, Pamplona, Santander, Santiago de Compostela, Valencia

2026-02-03

Not yet open

Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases

NCT07406126Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases

Fernando Gómez Muñoz

Observational

Pamplona, Castelló, Granada, Madrid, Valencia

2026-02

Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

NCT07288177Non-small Cell Lung Cancer (NSCLC)

DrugRina-S

Genmab

Phase 2

240

A Coruña, Barcelona, Las Palmas de Gran Canaria, Logroño, Madrid, Málaga, Pamplona, Valencia

2026-01-30

Active, closed

Diactive-1: Scaled-up Personalized mHealth Program for Youth With Type 1 Diabetes

NCT07290868Type 1 Diabetes (T1D)

Fundacion Miguel Servet

Not applicable

158

Pamplona

2026-01-28

Recruiting

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190Uveal Melanoma

DrugDarovasertib

IDEAYA Biosciences

Phase 3

520

Santiago de Compostela, L'Hospitalet de Llobregat, Pamplona, Valencia, Valladolid, Seville

2026-01-25

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab

Boehringer Ingelheim

Phase 3

400

Barcelona, Burgos, Elche, Jerez de la Frontera, Madrid, Majadahonda, Málaga, Pamplona

2026-01-16

Recruiting

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

240

Barcelona, Pamplona

2026-01-15

Recruiting

External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis

NCT07418099Coagulation Disorder, Blood, Prolonged APTT

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Observational

1,500

Leganés, Barcelona, Lleida, Madrid, Murcia, Pamplona, Salamanca, Santiago de Compostela

2026-01-13

Recruiting

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

NCT07226427Platinum-resistant Ovarian Cancer

Stemline Therapeutics, Inc.

Phase 1

100

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón

2026-01-10

Recruiting

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

NCT07223697Atopic Dermatitis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

120

Pamplona, Córdoba

2026-01-08

Recruiting

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452Multiple Myeloma

DrugsEtentamig·Daratumumab·Lenalidomide·Dexamethasone

AbbVie

Phase 2/3

680

Santiago de Compostela, Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, León, Madrid

2026-01-08

Recruiting

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT07227454Depressive Disorder, Major

DrugsEsketamine·Midazolam

Janssen Research & Development, LLC

Phase 3

258

Barcelona, Esplugues de Llobregat, Madrid, Manresa, Oviedo, Pamplona, Sabadell

2026-01-08

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer

DrugsPumitamig·Folfox·Bevacizumab

Bristol-Myers Squibb

Phase 2/3

990

Santiago de Compostela, Barcelona, Madrid, Pamplona, Badalona, Elche (alicante), Málaga, Salamanca

2025-12-31

Recruiting

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

NCT07138196Chronic Graft-Versus-Host Disease

DrugAdrixetinib

Qurient Co., Ltd.

Phase 1

Barcelona, Madrid, Majadahonda, Murcia, Pamplona, Santander, Seville, Valencia

2025-12-23

Recruiting

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

NCT06975787Lupus Nephritis (LN)

DrugsVonsetamig·Odronextamab

Regeneron Pharmaceuticals

Phase 1

Seville, Pamplona, Madrid, Málaga

2025-12-22

Recruiting

Intervascular Post-Market Clinical Follow-Up (PMCF) Registry

NCT07322913Carotid Artery Diseases, Aortic Diseases, Peripheral Arterial Diseases

Intervascular

Observational

1,200

Pamplona

2025-12-19

Active, closed

WATCHMAN FLX Pro European Registry

NCT07262255Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure

Boston Scientific Corporation

Observational

189

León, Pamplona, Pontevedra, Salamanca

2025-12-17

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

DrugCetuximab

Revolution Medicines, Inc.

Phase 3

500

Pamplona, Barcelona, Madrid, Seville, Valencia

2025-12-15

Recruiting

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

NCT07293754Advanced Malignant Solid Tumor

Repertoire Immune Medicines

Phase 1/2

150

Barcelona, Logroño, Madrid, Pamplona, Valencia

2025-12-12

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

500

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santiago de Compostela, Valencia, Zaragoza

2025-12-03

Active, closed

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

NCT07299097Narcolepsy Type 1, Narcolepsy Type 2

Takeda

Observational

402

Castellon, Pamplona, Alzira, Barcelona, Granada, Madrid, Seville, Vitoria-Gasteiz

2025-12-02

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229Alzheimer Disease, Agitation

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

650

Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa

2025-12-02

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

NCT07196644Solid Tumors Harboring MET Amplification

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

100

Pamplona, Barcelona, Madrid, Valencia

2025-12-01

Recruiting

Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2).

NCT07165431Nutrition, Healthy, Weight Loss, Overweight and Obesity

Clinica Universidad de Navarra, Universidad de Navarra

Not applicable

114

Pamplona

2025-12-01

Recruiting

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

NCT07218146Small-cell Lung Cancer

DrugZL-1310

Zai Lab (Shanghai) Co., Ltd.

Phase 3

480

Valencia, Barcelona, Elche, Girona, Jerez de la Frontera, Madrid, Málaga, Pamplona

2025-11-30

Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel

Amgen

Phase 3

750

Málaga, Barcelona, L'Hospitalet de Llobregat, A Coruña, Lugo, Majadahonda, Pamplona, Madrid

2025-11-28

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer

DrugRina-S

Genmab

Phase 3

660

Palma de Mallorca, Barcelona, Girona, A Coruña, Madrid, Málaga, Pamplona, Valencia

2025-11-28

Recruiting

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Alexion Pharmaceuticals, Inc.

Phase 2

Barcelona, Pamplona, San Sebastián de los Reyes, Santander, Seville

2025-11-26

Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 1/2

152

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Valencia

2025-11-24

Recruiting

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778Symptomatic Venous Thromboembolism (VTE)

DrugsCenvacibart·Acetylsalicylic acid

Regeneron Pharmaceuticals

Phase 3

2,000

Vitoria-Gasteiz, Marbella, Pamplona, Barcelona, Madrid, Valencia

2025-11-24

Active, closed

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

NCT07187115Atrial Fibrillation (AF), Persistant Atrial Fibrillation

Boston Scientific Corporation

Not applicable

699

Pamplona

2025-11-07

Recruiting

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

NCT07064122Haematologic Neoplasms

AstraZeneca

Phase 1

Barcelona, Madrid, Pamplona, Salamanca, Valencia

2025-11-03

Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751Breast Neoplasms

DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin

BioNTech SE

Phase 3

558

Badajoz, Barcelona, Córdoba, Madrid, Murcia, Pamplona, Sabadell, Valencia

2025-10-30

Recruiting

Monitoring Coughs for the Early Detection of Worsening COPD

NCT07212439Chronic Obstructive Pulmonary Disease (COPD)

Clinica Universidad de Navarra, Universidad de Navarra

Observational

Pamplona

2025-10-29

Recruiting

PKB171 Against Placebo in Couples With Mild Male Factor Infertility

NCT07669584Infertility Due to Azoospermia

Prokrea BCN, S.L.

Phase 2/3

732

Pamplona, Barcelona, Madrid, Seville

2025-10-28

Recruiting

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

NCT07377045Pancreatic Adenocarcinoma Metastatic

DrugsOMTX705·Nab-paclitaxel·Tislelizumab·Gemcitabine

Oncomatryx Biopharma S.L.

Phase 1

Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Madrid, Pamplona, Santiago de Compostela

2025-10-28

Recruiting

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 3

600

Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, Madrid, Málaga, Seville

2025-10-24

Recruiting

A Study of ZW251 in Participants With Advanced Solid Tumors

NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor

Zymeworks BC Inc.

Phase 1

140

Barcelona, Logroño, Madrid, Málaga, Pamplona

2025-10-21

Recruiting

Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases

NCT07447440Breast Cancer, Health, Subjective, Obesity

Clinica Universidad de Navarra, Universidad de Navarra

Observational

Pamplona

2025-10-15

Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

NCT07160725Solid Tumours

DrugPumitamig

Bristol-Myers Squibb

Phase 1/2

540

Málaga, Badalona, Barcelona, Pamplona, Madrid

2025-10-15

Recruiting

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

NCT07284277Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma

Clinica Universidad de Navarra, Universidad de Navarra

Phase 1/2

Pamplona, Barakaldo, Galdakao, Madrid, Vitoria-Gasteiz

2025-10-14

Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857Multiple Myeloma

DrugsCilta-cel·Fludarabine·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Seville

2025-10-03

By invitation

MRI-guided Locoregional SBRT Prostate Program

NCT07132073Prostate Cancer

Clinica Universidad de Navarra, Universidad de Navarra

Not applicable

Pamplona

2025-10-01

Recruiting

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT07389265Metastatic Colorectal Cancer (mCRC)

DrugsFOLFOX (Folinic acid·Erbitux·Folfox·Fluorouracil

University of Campania Luigi Vanvitelli

Phase 3

480

Barcelona, Cartagena, Córdoba, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2025-10-01

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Valencia

2025-10-01

Active, closed

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

NCT07210463Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors

DrugXeomin

Merz Aesthetics GmbH

Phase 3

300

Pamplona, Valencia

2025-10-01

Not yet open

Better4All Personalized Intervention

NCT06997510Obesity Prevention

Harokopio University

Not applicable

1,022

Pamplona

2025-10-01

Not yet open

Effect of a Person-Centred Care Intervention for Families Providing Home-Based Care to a Person With Advanced Chronic Illness: A Pilot Randomised Controlled Trial

NCT07184216Chronic Illness, Caregivers

Clinica Universidad de Navarra, Universidad de Navarra

Not applicable

Pamplona

2025-10-01

Recruiting

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275Primary Membranous Nephropathy

DrugsPovetacicept·Tacrolimus

Vertex Pharmaceuticals Incorporated

Phase 2/3

176

Barcelona, Córdoba, Elche, Lugo, Pamplona, Seville

2025-09-30

Recruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

200

Barcelona, Madrid, Pamplona, Seville, Valencia

2025-09-30

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

NCT07285590Mantle Cell Lymphoma (MCL)

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Marbella, Pamplona, Salamanca

2025-09-30

Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Non-small Cell Lung Cancer

DrugsBNT326·Pumitamig

BioNTech SE

Phase 1/2

880

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2025-09-22

Recruiting

A Study to Evaluate the Safety and Performance of a Vestibular Implant in Adults to Provide Balance Restoration

NCT06805175Vestibulopathy, Moderate to Severe Hearing Loss, Normal Hearing, Balance Deficits

Cochlear

Not applicable

Las Palmas de Gran Canaria, Pamplona

2025-09-18

Not yet open

Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients

NCT07153406Depressive Disorder

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 3

220

Pamplona, Barcelona, Palencia, Sabadell, Seville

2025-09-15

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Santander, Seville

2025-09-08

Not yet open

Effect of Probiotic Intake in Healthy Population

NCT07165457Adverse Effects, Healthy

Clinica Universidad de Navarra, Universidad de Navarra

Not applicable

Pamplona

2025-09-04

Recruiting

A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

NCT06984627Graves' Disease

DrugRilzabrutinib

Sanofi

Phase 2

Barcelona, Pamplona, Seville

2025-09-02

By invitation

Exercise During Pregnancy: Effects on the Maternal-Fetal Unit

NCT07264231Pregnancy

Universidad Pública de Navarra

Not applicable

Pamplona

2025-09-01

Not yet open

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

NCT07124884Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer

Federation Francophone de Cancerologie Digestive

Phase 2

300

Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Oviedo, Pamplona, Salamanca, San Carlos

2025-08-31

Recruiting

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsLeucovorin·Adrucil·Tislelizumab·Capecitabine

BeOne Medicines

Phase 3

351

Barcelona, Pamplona, Valencia, Zaragoza

2025-08-27

Recruiting

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 2/3

153

Oviedo, Santiago de Compostela, Pamplona

2025-08-21

Recruiting

Impact of Satiating Compounds and Hypocaloric Diet on Weight, Cardiometabolic and Osteoarticular Health in Obesity

NCT07165548Obesity, Overweight

Clinica Universidad de Navarra, Universidad de Navarra

Not applicable

144

Pamplona

2025-08-20

Recruiting

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

NCT06892054Pancreatic Adenocarcinoma

DrugSotorasib

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Phase 1

Zaragoza, Barcelona, Santander, Córdoba, Donostia / San Sebastian, Madrid, Málaga, Pamplona

2025-08-08

Recruiting

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

NCT07094516Alzheimer's Disease

DrugVHB937

Novartis Pharmaceuticals

Phase 2

407

Pamplona, Valencia

2025-08-07

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Santiago de Compostela, Seville, Esplugues de Llobregat, Bizkaia, Barcelona, Alcalá de Henares, Madrid, Pamplona

2025-08-06

Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsPemetrexed /m^2·Carboplatin (AUC 5)·Visugromab·Visugromab RDE

CatalYm GmbH

Phase 2

107

Jaén, Málaga, Seville, Santander, Barcelona, Pamplona, Santiago de Compostela, Rioja

2025-08-01

Recruiting

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

NCT06721013Immune Thrombocytopenia (ITP)

DrugPirtobrutinib

Eli Lilly and Company

Phase 1/2

Barcelona, Burgos, Murcia, Pamplona

2025-07-30

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Badalona, Barakaldo, Pamplona, Barcelona, Madrid, Seville

2025-07-15

Recruiting

Impact of Physical Exercise on Hospitalized Older Adults Malnourished or at Risk, With Oral Nutritional Support

NCT07067697Hospitalized, Older Adults, Physical Exercise, Oral Nutritional Supplementation

Fundacion Miguel Servet

Not applicable

102

Pamplona

2025-07-14

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Seville, Sant Cugat del Vallès, Barcelona, Lleida, Pamplona, Madrid

2025-07-14

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732Alzheimer Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

426

Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa

2025-07-10

Recruiting

Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)

NCT07067437Breast Neoplasms

National Institute of Oncology, Hungary

Not applicable

250

Barcelona, Pamplona, Valencia

2025-07-01

Recruiting

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

NCT07045909De Novo Multiple Myeloma, Anitocabtagene Autoleucel

DrugsAnitocabtagene Autoleucel·Isatuximab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville

2025-06-30

Recruiting

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

NCT07483827C3 Glomerulopathy (C3G), Healthy Adult Participants

eleva GmbH

Phase 1

Barcelona, Madrid, Pamplona, Seville

2025-06-26

Recruiting

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099Crohn's Disease, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

290

Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia

2025-06-26

Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086Ulcerative Colitis, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

350

Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia

2025-06-26

Recruiting

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

NCT06885034Gastrointestinal Neoplasms

DrugRisvutatug rezetecan

GlaxoSmithKline

Phase 1/2

451

Barcelona, HebrOn, Madrid, Pamplona, Santander, Zaragoza

2025-06-11

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

A Coruña, Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón

2025-06-04

Recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125Dravet Syndrome

DrugZorevunersen

Stoke Therapeutics, Inc

Phase 3

170

Madrid, Pamplona

2025-06-04

Recruiting

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627Venous Leg Ulcer (VLU)

DrugEscharEx

MediWound Ltd

Phase 3

216

Barcelona, Madrid, Pamplona

2025-06-01

Recruiting

Better4All Personalized Intervention Pilot Study

NCT07120802Obesity Prevention

Harokopio University

Not applicable

490

Pamplona

2025-06-01

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers

DrugsMIRV·Mirvetuximab Soravtansine

AbbVie

Phase 2

110

Badalona, Jaén, El Palmar, Pamplona, Seville, Barcelona, Madrid, Valencia

2025-05-28

Recruiting

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 2

Barcelona, Pamplona, Alicante, Madrid

2025-05-22

Active, closed

FARAPULSE Workflow Assessment Registry

NCT06656884Atrial Fibrillation (AF)

Boston Scientific Corporation

Observational

524

Barcelona, El Palmar, Pamplona, Santa Cruz de Tenerife

2025-05-06

Active, closed

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)

DrugsPelacarsen·Inclisiran

Novartis Pharmaceuticals

Phase 3

246

Santiago Compostela, Pamplona, Castilleja de la Cuesta, A Coruña, Barcelona, Córdoba, Huelva, Las Palmas GC

2025-04-30

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

NCT06884618Neoplasms

Hoffmann-La Roche

Phase 1

405

Pamplona, Barcelona, Madrid

2025-04-30

Recruiting

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463Metastatic Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Panitumumab·Fluorouracil·Leucovorin

AbbVie

Phase 2

390

Santander, Pamplona, Barcelona, Madrid, Valencia

2025-04-24

Recruiting

EMBRACE Tremor BiFUS

NCT06974916Essential Tremor

InSightec

Not applicable

100

Badalona, Móstoles, Pamplona, Valencia

2025-04-22

Recruiting

Reproducibility of Multiparametric Renal Magnetic Resonance Imaging on 1.5T MRI Scanners

NCT06884410Multiparametric MRI

Mario Negri Institute for Pharmacological Research

Not applicable

Pamplona

2025-04-12

Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217Lennox Gastaut Syndrome

DrugClemizole HCl

Epygenix

Phase 3

260

Barcelona, Madrid, Málaga, Pamplona, Seville

2025-04-09

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961Atopic Dermatitis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

162

Santiago de Compostela, Pamplona, Córdoba, Madrid

2025-04-01

By invitation

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

300

Barcelona, Majadahonda, Pamplona, Málaga, Valencia

2025-04-01

Not yet open

Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia

NCT06830733Leukemia, Plasma Cell

Fundacion Clinic per a la Recerca Biomédica

Phase 2

Santander, Madrid, Murcia, Pamplona, Salamanca, Barcelona

2025-04

Recruiting

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06980116Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL)

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Phase 1

Madrid, Pamplona

2025-03-31

Recruiting

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

NCT06830759Diffuse Large B-cell Lymphoma, Follicular Lymphoma

AbbVie

Observational

700

A Coruña, Badalona, Sabadell, Córdoba, Marbella, Pamplona, Seville, Manises

2025-03-28

Recruiting

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

NCT06795022Hepatocellular Carcinoma

AstraZeneca

Phase 1/2

304

Barcelona, Pamplona

2025-03-27

Recruiting

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

NCT06644781Esophageal Squamous Cell Carcinoma

DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel

Daiichi Sankyo

Phase 3

510

Burgos, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Ourense, Oviedo, Pamplona

2025-03-27

Recruiting

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

NCT06914128MTAP-deleted Solid Tumors

Bayer

Phase 1/2

450

Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Málaga, Valencia, Pamplona

2025-03-21

Active, closed

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06651229Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms

DrugsAzacitadine·Venetoclax

Janssen Research & Development, LLC

Phase 1

Madrid, Pamplona, Seville

2025-03-21

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007Ovarian Cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Daiichi Sankyo

Phase 3

582

A Coruña, Barcelona, Córdoba, El Palmar, Madrid, Palma, Pamplona, Planta Baja

2025-03-19

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Barakaldo, Barcelona, Granada, Madrid, Málaga, Palma de Mallorca, Pamplona, Seville

2025-03-18

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Santiago de Compostela, Palma, Badalona, Pamplona, Granada, Salamanca

2025-03-12

Recruiting

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Barcelona, Madrid, Málaga, Pamplona, Santander, Valencia

2025-03-12

Active, closed

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858839Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

3,853

Almería, Castilleja de la Cuesta, Huelva, Sanlúcar de Barrameda, Seville, A Coruña, Pozuelo de Alarcón, Pamplona

2025-03-12

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis

DrugZugo-cel

CRISPR Therapeutics

Phase 1

Córdoba, Pamplona, Seville

2025-03-10

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Majadahonda, Málaga, Palma deMallorca, Pamplona

2025-03-03

Recruiting

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

NCT06764316Hepatocellular Carcinoma

Bayer

Phase 1

148

Barcelona, Madrid, Pamplona

2025-02-28

Recruiting

The Use of Combined Motor Imagery and Action Observation to Evaluate the Influence on Functional Parameters Such as Strength, Range of Motion, Pain or Fear of Movement Among Others, in Females Breast Cancer Survivors.

NCT07067710Breast Cancer Survivor

Fundacion Miguel Servet

Not applicable

108

Pamplona

2025-02-25

Active, closed

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

Badalona, Pamplona, Burjassot, Madrid, Málaga

2025-02-19

Recruiting

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197Advanced Solid Tumors

DrugsNivolumab and rHuPH20·Opdualag·Bevacizumab

Bristol-Myers Squibb

Phase 1/2

413

Barcelona, Pamplona, Madrid

2025-02-17

By invitation

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

324

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia

2025-02-12

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

216

Barcelona, Santander, L'Hospitalet de Llobregat, Pamplona, Madrid

2025-02-06

Recruiting

Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry

NCT06163807Chronic Asthma

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Observational

1,200

Santiago de Compostela, Badalona, Barcelona, A Coruña, Madrid, Pamplona

2025-02-01

Recruiting

Multicomponent Exercise to Prevent Hospitalization-Associated Disability

NCT07707310Clinical Deterioration

Fundacion Miguel Servet

Not applicable

300

Pamplona

2025-02-01

Recruiting

Prevention of Functional and Cognitive Impairment Through a Multicomponent Exercise Program in Hospitalized Older Adults

NCT06634147Clinical Deterioration

Fundacion Miguel Servet

Not applicable

296

Pamplona

2025-02-01

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Badalona, Barcelona, Madrid, Pamplona, Santander, Valencia

2025-01-28

Active, closed

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

NCT06133517Urothelial Bladder Carcinoma

DrugsDomvanalimab·Zimberelimab·Sacituzumab Govitecan

Fundación para el Progreso de la Oncología en Cantabria

Phase 2

L'Hospitalet de Llobregat, Santander, Madrid, Pamplona, Toledo, Valladolid

2025-01-20

By invitation

Effects of a Multicomponent Training Program on Cardiac Function, Skeletal Muscle Metabolism, Functional Capacity, and Quality of Life in Patients With HFpEF: SENSORFIT-4HEART Study

NCT07251361Heart Failure With Preserved Ejection Fraction (HFPEF)

Universidad Pública de Navarra

Not applicable

150

Pamplona

2025-01-20

Active, closed

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06618001Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms

Janssen Research & Development, LLC

Phase 1

Barcelona, Madrid, Pamplona

2025-01-14

Not yet open

SHARE Study: Social Chronic Heart Failure Person-centred cARE Intervention

NCT06701916Heart Failure

Clinica Universidad de Navarra, Universidad de Navarra

Not applicable

374

Pamplona

2025-01-10

Recruiting

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

NCT06227910Crohn's Disease

DrugsVedolizumab·Upadacitinib

Takeda

Phase 3

396

Madrid, Palma, Pamplona, Santiago de Compostela, Valencia

2025-01-02

By invitation

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes

DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib

Janssen Research & Development, LLC

Phase 1

120

Barcelona, Madrid, Pamplona, Salamanca

2024-12-30

Active, closed

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Phase 1

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2024-12-19

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

240

Badalona, Barcelona, Córdoba, Granada, Madrid, Pamplona, Seville

2024-12-17

Active, closed

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256Idiopathic Inflammatory Myopathies

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca

2024-12-17

Recruiting

DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.

NCT06657833Coronary Artery Disease

Fundación EPIC

Not applicable

128

Barcelona, Fuencarral-El Pardo, Galdakao, L'Hospitalet de Llobregat, León, Madrid, Moncloa-Aravaca, Pamplona

2024-12-17

Active, closed

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsBudigalimab·Telisotuzumab Adizutecan·Fluorouracil·Leucovorin

AbbVie

Phase 2

185

Pamplona, Madrid, Ourense, Valencia

2024-12-13

Active, closed

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma

DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine

Arcus Biosciences, Inc.

Phase 3

610

Barcelona, Elche, Girona, Madrid, Pamplona, Vigo, Zaragoza

2024-12-13

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Badajoz, Barcelona, Madrid, Málaga, Pamplona, Seville, Valencia

2024-12-12

By invitation

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)

DrugRAY121

Chugai Pharmaceutical

Phase 1

144

Pamplona, Madrid, Barcelona, Córdoba, Seville, Valencia

2024-12-09

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Elche, Cadiz, Badalona, Esplugues, Pamplona, Barcelona, Málaga, Seville

2024-12-09

Active, closed

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide

Amgen

Phase 3

707

Málaga, Seville, Barcelona, Pamplona, Valencia, Madrid

2024-12-09

Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908Carcinoma, Non-Small-Cell Lung

DrugsJNJ-90301900·Durvalumab

Johnson & Johnson Enterprise Innovation Inc.

Phase 2

130

Madrid, Pamplona, Santiago de Compostela, Valencia

2024-12-06

Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

NCT06534437Non-Hodgkin Lymphoma, B-cell

DrugGlofitamab

Ryvu Therapeutics SA

Phase 2

178

Barcelona, Madrid, Murcia, Pamplona, Salamanca, Seville, Zaragoza

2024-12-05

Recruiting

Multicomponent Prehabilitation in Older Adults With Breast Cancer

NCT07531836Breast Cancer, Frailty, Sarcopenia, Aging

Fundacion Miguel Servet

Not applicable

Pamplona

2024-12-04

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Barcelona, Huelva, Madrid, Pamplona, Santander, Seville

2024-12-04

Recruiting

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2024-12-03

Recruiting

Impact of Creatine Monohydrate Micronized Supplementation With or Without Multicomponent Training in Older Adults.

NCT06677359Functionality, Cognition, Strength Training Effects

Fundacion Miguel Servet

Not applicable

120

Pamplona

2024-11-30

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

L'Hospitalet de Llobregat, Córdoba, Santiago de Compostela, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Marbella, Pamplona, Alicante

2024-11-25

Recruiting

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

NCT06458712Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)

Duke Street Bio Ltd

Phase 1

180

Logroño, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-11-21

Active, closed

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329Non-Small Cell Lung Cancer

DrugsMarlotamig·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

120

Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Madrid, Seville, Valencia, Zaragoza

2024-11-18

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia

2024-11-11

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca

2024-10-29

Recruiting

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT06667960Solid Tumor

Salubris Biotherapeutics Inc

Phase 1/2

255

Barcelona, Madrid, Pamplona, Rioja, Valencia

2024-10-23

Recruiting

The Sagittarius Trial

NCT06490536Colon Cancer Stage II, Colon Cancer Stage III

DrugsFolinic acid·Panitumumab·Pertuzumab·Temozolomide

IFOM ETS - The AIRC Institute of Molecular Oncology

Phase 3

700

Barcelona, Valencia, Córdoba, Madrid, Pamplona, Santander, Santiago de Compostela, Zaragoza

2024-10-22

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Barcelona, Madrid, Pamplona, Seville, Valencia

2024-10-18

Active, closed

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsLiposomal Irinotecan·Leucovorin·Irinotecan·Cetuximab

Revolution Medicines, Inc.

Phase 3

500

Barcelona, Madrid, Pamplona, Valencia

2024-10-16

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

A Coruña, Badalona, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-10-11

Active, closed

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

349

Barakaldo, Barcelona, Elche, Madrid, Pamplona, Seville, Valencia

2024-10-02

Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

DrugsNadofaragene Firadenovec·Docetaxel·Gemcitabine·Pembrolizumab

Ferring Pharmaceuticals

Phase 3

250

Santander, Barcelona, Córdoba, A Coruña, Alcorcón, Madrid, Pamplona, Bilbao

2024-10-01

Recruiting

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

NCT06622486Solid Tumor, Adult

Egle Therapeutics

Phase 1/2

Barcelona, Madrid, Pamplona, Valencia

2024-09-27

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga

2024-09-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Badalona, Barcelona, Madrid, Marbella, Pamplona, Valencia

2024-09-25

Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148Geographic Atrophy, Macular Degeneration

Janssen Research & Development, LLC

Phase 2/3

274

Barcelona, Burjassot, Córdoba, Madrid, Majadahonda, Pamplona, Sant Cugat del Vallès, Seville

2024-09-19

Active, closed

A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors

NCT06537310Cancer-Neoplasms

Hoffmann-La Roche

Phase 1

Pamplona, Barcelona, Madrid

2024-09-16

Active, closed

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

NCT06243458Low Risk Myelodysplastic Syndromes

DrugRVU120

GCP-Service International West GmbH

Phase 2

Barcelona, León, Madrid, Pamplona, Salamanca, Valencia

2024-09-10

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

DrugGlofitamab

Arvinas Inc.

Phase 1

329

El Palmar, Pamplona, Barcelona, Madrid, Salamanca

2024-09-05

Active, closed

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

179

Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Salamanca, Valencia

2024-09-04

Recruiting

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271Systemic Lupus Erythematosus

DrugBelimumab

GlaxoSmithKline

Phase 1

142

Barcelona, Bilbao, Pamplona, Sabadell Barcelona, Valladolid

2024-09-02

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Barcelona, Córdoba, Lleida, Madrid, Pamplona, Santiago de Compostela, Seville, Valencia

2024-08-30

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

555

Badalona, Majadahonda, Pamplona, A Coruña, Barcelona, Madrid, Valencia

2024-08-28

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

A Coruña, Alcorcón, Barcelona, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela

2024-08-27

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Badalona, Barcelona, El Palmar, Madrid, Pamplona, Salamanca, Santander, Seville

2024-08-23

Recruiting

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy

DrugsRiliprubart·IVIG

Sanofi

Phase 3

160

Santiago de Compostela, Barcelona, Majadahonda, Pamplona, Málaga, Sabadell, Santa Cruz de Tenerife, Valencia

2024-08-21

Recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)

DrugRAY121

Chugai Pharmaceutical

Phase 1

144

Pamplona, Madrid, Barcelona, Córdoba, Seville, Valencia

2024-08-19

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Barcelona, El Palmar, Girona, Las Palmas de Gran Canaria, Madrid, Oviedo, Pamplona, Santander

2024-08-07

Recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

NCT06292780Relapsed/Refractory Systemic Light Chain Amyloidosis

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

220

Palma, Pamplona, Gijón, Barcelona, Valencia

2024-08-07

Recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019Chronic Lymphocytic Leukemia

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AbbVie

Phase 3

170

Santiago de Compostela, Majadahonda, Pamplona, Madrid, Seville

2024-08-05

Active, closed

Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis

DrugsIptacopan·Rituximab

Novartis Pharmaceuticals

Phase 2

Plasencia, Pamplona, Madrid

2024-08-05

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

A Coruña, Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2024-08-01

Active, closed

A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease

NCT06584383Parkinson Disease

InSightec

Not applicable

Móstoles, Pamplona

2024-08-01

Recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

NCT06216301Metastatic Non-small Cell Lung Cancer

DrugPembrolizumab

NovoCure GmbH

Phase 3

734

Elche, Seville, Barcelona, Torrejón de Ardoz, Lleida, Madrid, Málaga, Pamplona

2024-07-31

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-07-30

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-07-23

Active, closed

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

NCT06384261Leukemia, Myeloid, Acute

DrugsCusatuzumab·Azacitidine·Venetoclax

OncoVerity, Inc.

Phase 2

140

Barcelona, Pamplona, Salamanca

2024-07-22

Active, closed

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616Alzheimer Disease

Janssen Pharmaceutica N.V., Belgium

Phase 2

Barcelona, Getxo, Lleida, Madrid, Pamplona, Pozuelo de Alarcón, Sant Cugat del Vallès, Terrassa

2024-07-22

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Santiago de Compostela, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-07-19

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Barcelona, Cadiz, Madrid, Pamplona, Pozuelo de Alarcón, Seville, Torrejón de Ardoz, Valencia

2024-07-19

Active, closed

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

NCT06161441Resectable Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Taxol

Regeneron Pharmaceuticals

Phase 2

195

Santiago de Compostela, Elche, Granada, Palma, Barcelona, Majadahonda, El Palmar, Pamplona

2024-07-16

Active, closed

Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study

NCT06149650Chronic Limb-Threatening Ischemia

Cardiovascular and Interventional Radiological Society of Europe

Observational

400

Alicante, Granollers, Pamplona

2024-07-15

Active, closed

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

109

Santiago de Compostela, Barcelona, Bilbao, Majadahonda, Pamplona, Oviedo, Sabadell, Santa Cruz de Tenerife

2024-07-12

Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180Advanced Melanoma

DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Nivolumab

Replimune, Inc.

Phase 3

400

Barcelona, El Palmar, Madrid, Pamplona

2024-07-11

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Barcelona, Madrid, Pamplona, Valencia

2024-06-25

Active, closed

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor

DrugsTemodar·Niraparib·Temozolomide

Ivy Brain Tumor Center

Phase 3

450

Barcelona, Córdoba, Girona, Madrid, Pamplona, Salamanca, Seville

2024-06-19

Recruiting

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

NCT06504147Peritoneal Carcinomatosis, Ovarian Cancer

Oncoinvent Solutions AS

Phase 2

114

Barcelona, Madrid, Pamplona, Valencia

2024-06-15

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

A Coruña, Barcelona, Girona, Madrid, Pamplona, Seville, Valencia, Zaragoza

2024-06-07

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2024-06-07

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Málaga, Seville, Barcelona, L'Hospitalet de Llobregat, Pamplona, Valencia, Madrid

2024-06-05

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06507306Solid Tumor, Adult

DrugsKQB198·Tagrisso·Amivantamab·Osimertinib

Kumquat Biosciences Inc.

Phase 1

Barcelona, Madrid, Málaga, Pamplona

2024-06-03

Active, closed

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification

DrugsELVN-002·Eribulin·Leucovorin·Trastuzumab

Enliven Therapeutics

Phase 1

275

Barcelona, Madrid, Pamplona, Valencia

2024-05-30

Active, closed

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

NCT05735834Splenic Marginal Zone Lymphoma

DrugsTruxima·Zanubrutinib·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 3

122

Barcelona, Bilbao, El Palmar, Madrid, Pamplona, Salamanca, San Sebastián, Valencia

2024-05-21

Recruiting

Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality

NCT06338215All Cause Mortality, Cardiovascular Diseases, Invasive Cancer, Liver Cirrhosis

Clinica Universidad de Navarra, Universidad de Navarra

Not applicable

10,000

Pamplona

2024-05-15

Active, closed

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugsKeytruda·Pembrolizumab

Inhibrx Biosciences, Inc

Phase 2/3

410

Santiago, Barcelona, Pamplona, Madrid, A Coruña, Valencia

2024-05-14

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-05-13

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Esplugues de Llobregat, Bilbao, Las Palmas de Gran Canaria, Pamplona, Vigo, Seville, Burjassot - Valencia, Alicante

2024-05-08

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

450

Santander, A Coruña, Pamplona, Oviedo, Barcelona, Madrid

2024-05-03

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Andalucia, Barcelona, Cadiz, Galícia, Madrid, Pamplona

2024-04-29

Recruiting

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor

DrugXmAb541

Xencor, Inc.

Phase 1

282

Barcelona, Madrid, Pamplona

2024-04-04

Recruiting

Immersive Virtual Reality and Physical Exercise on Cognitive and Functional Performance in Hospitalized Older Patients

NCT06340282Disability Physical, Cognition

Fundacion Miguel Servet

Not applicable

212

Pamplona

2024-04-01

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875Ulcerative Colitis

DrugsLutikizumab·Humira·Adalimumab

AbbVie

Phase 2

156

Santiago de Compostela, Pamplona, Madrid, Seville

2024-03-23

Recruiting

Study of AZD0754 in Participants With Metastatic Prostate Cancer

NCT06267729Metastatic Prostate Cancer

DrugsAZD0754·AZD2287

AstraZeneca

Phase 1/2

Pamplona

2024-03-12

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

NCT06378190Refractory B-Cell Lymphoma, B-cell Lymphoma Recurrent

Instituto de Investigación Biomédica de Salamanca

Phase 1/2

Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Pamplona, Salamanca, Seville

2024-03-11

Active, closed

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

NCT05643638Graft Versus Host Disease, Acute

Cynata Therapeutics Limited

Phase 2

Barcelona, Madrid, Murcia, Pamplona

2024-03-04

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Barcelona, Jaén, Madrid, Pamplona, Valencia

2024-02-27

Active, closed

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530Non-small Cell Lung Cancer

DrugDurvalumab

AstraZeneca

Phase 2

142

Barakaldo, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia, Zaragoza

2024-02-22

Recruiting

Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

NCT06099119Unresectable Pancreatic Cancer

Hospital Clinico Universitario de Santiago

Phase 4

100

Santiago de Compostela, Pamplona

2024-02-20

Recruiting

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

NCT06121297Systemic Lupus Erythematosus, Lupus Nephritis

DrugRese-cel

Cabaletta Bio

Phase 1/2

Pamplona

2024-02-16

Active, closed

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

NCT06230224B-Cell Non-Hodgkin Lymphoma (B-NHL)

DrugsOdronextamab·Ifosfamide·Paraplatin·Cytarabine

Regeneron Pharmaceuticals

Phase 3

216

Palma, Madrid, Pamplona, Valencia

2024-02-15

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Badalona, L'Hospitalet de Llobregat, Santander, Pamplona, Barcelona, Cáceres, Madrid, Salamanca

2024-02-05

Active, closed

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

NCT05955508Smoldering Multiple Myeloma (SMM)

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 2

Santiago de Compostela, Granada, Palma Mallorca, Badalona, Santander, Pozuelo de Alarcón, El Palmar, Pamplona

2024-01-30

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT06004245Advanced Solid Tumors, Colorectal Cancer

DrugsVVD-133214·Avastin·Keytruda·Bevacizumab

Vividion Therapeutics, Inc.

Phase 1

280

Barcelona, Madrid, Pamplona, Valencia

2024-01-25

Active, closed

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596Metastatic Urothelial Cancer

DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin

BicycleTx Limited

Phase 2

375

Barcelona, Las Palmas de Gran Canaria, Madrid, Pamplona, San Sebastián, Santander, Santiago de Compostela, Valencia

2024-01-24

Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06153251Relapsed and/or Refractory Multiple Myeloma

DrugsFludara·Cytoxan·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

187

Pamplona, Salamanca

2024-01-23

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Barcelona, Sant Cugat del Vallès, Santiago de Compostela, Madrid, Majadahonda, Pozuelo de Alarcón, Málaga, Pamplona

2024-01-18

Recruiting

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed

Revolution Medicines, Inc.

Phase 1/2

616

Madrid, Pamplona, Valencia, A Coruña, Barcelona, Málaga, Seville

2024-01-18

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197Heart Failure, Acute Heart Failure

DrugsKerendia·Finerenone

Colorado Prevention Center

Phase 3

5,200

Villamartín, Zaragoza, Badalona, Sanlúcar de Barrameda, A Coruña, Santiago de Compostela, Pamplona, Barcelona

2024-01-17

Recruiting

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

NCT07249060Immune-Related Adverse Events, Lupus Erythematosus, Systemic, Sjogren Syndrome, Systemic Sclerosis (SSc)

Hospital Universitario Araba

Observational

300

Pamplona

2024-01-08

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

NCT06191263Acute Myeloid Leukemia

DrugsRVU120·Venetoclax

Ryvu Therapeutics SA

Phase 2

Barcelona, Cáceres, Madrid, Málaga, Pamplona, Seville, Valencia

2024-01-05

Recruiting

A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)

NCT06205953AL Amyloidosis

Fondazione IRCCS Policlinico San Matteo di Pavia

Observational

400

Pamplona

2024-01-01

Recruiting

Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)

NCT06379945Myelodysplastic Syndromes

Instituto de Investigación Biomédica de Salamanca

Observational

300

Badalona, Barcelona, Pamplona, Salamanca

2024-01-01

Recruiting

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

NCT05950945Breast Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

250

Barcelona, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Majadahonda, Murcia, Pamplona

2023-12-30

Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma

DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Truxima

Bristol-Myers Squibb

Phase 1/2

460

Málaga, Barcelona, Madrid, Pamplona, Salamanca

2023-12-29

Active, closed

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome

NS Pharma, Inc.

Phase 2

Santiago de Compostela, Pamplona

2023-12-20

Active, closed

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

200

Barcelona, Córdoba, Madrid, Pamplona, Santiago de Compostela, Zaragoza

2023-12-20

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

NCT05828511Multiple Myeloma

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

149

Badalona, Pozuelo de Alarcón, Pamplona, Oviedo, Alicante, Barcelona, Madrid, Salamanca

2023-12-19

Recruiting

Web-based Intervention for Long-term Breast Cancer Survivors

NCT05322460Long-term Effects of Cancer Treatment, Long-term Effects Secondary to Cancer Therapy in Adults

Cristina García-Vivar

Not applicable

182

Pamplona

2023-12-15

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130Advanced Solid Tumor

Eikon Therapeutics

Phase 1/2

156

Sabadell, Madrid, Pamplona, Barcelona, Seville, Valencia

2023-12-11

Active, closed

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

NCT06139406Lymphoma, Non-Hodgkin

DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543

Janssen Research & Development, LLC

Phase 1

Barcelona, Madrid, Pamplona, Salamanca

2023-12-06

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945Multiple Myeloma

DrugsElranatamab·Pomalidomide·Dexamethasone

AstraZeneca

Phase 1/2

226

Badalona, Madrid, Pamplona, Salamanca

2023-12-05

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

DrugsCamizestrant·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 1/2

564

Barcelona, Pamplona, Valencia

2023-12-05

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santander

2023-12-04

Active, closed

Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

NCT06150183Advanced Malignant Solid Tumor

DrugBNT314

BioNTech SE

Phase 1

Barcelona, Madrid, Pamplona

2023-11-30

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Alicante, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Oviedo, Pamplona, San Sebastián

2023-11-29

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Barcelona, Granada, Hospitalet deLlobregat, Madrid, Pamplona, Santander

2023-11-23

Active, closed

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Exemestane·Anastrozole·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

510

Badajoz, Badalona, Manresa, Girona, León, Lleida, Madrid, Pamplona

2023-11-16

Active, closed

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms

DrugDisitamab Vedotin

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

120

Pamplona, Córdoba, Madrid

2023-11-14

Active, closed

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

NCT06097364Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

733

Seville, Sabadell, Terrassa, Barakaldo, Majadahonda, Pozuelo de Alarcón, Pamplona, Oviedo

2023-11-14

Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

DrugsElironrasib·Cetuximab

Revolution Medicines, Inc.

Phase 1/2

534

Barcelona, Madrid, Pamplona, Seville, Valencia, Zaragoza

2023-11-14

Active, closed

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

NCT06075706Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 2

Madrid, Pamplona, Barcelona, Málaga, Murcia, Valencia

2023-11-13

Active, closed

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

NCT05784012Head and Neck Squamous Cell Carcinoma

DrugsNiraparib·Dostarlimab·Cisplatin

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 1/2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia

2023-11-13

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma

DrugsTelisotuzumab Adizutecan·Itraconazole·Bevacizumab

AbbVie

Phase 1

325

Badalona, Pamplona, Barcelona, Madrid, Málaga, Zaragoza

2023-11-09

Active, closed

TheraSphere With Durvalumab and Tremelimumab for HCC

NCT05063565Hepatocellular Carcinoma

Boston Scientific Corporation

Phase 2

100

Barcelona, Pamplona, Oviedo, Madrid, Valencia, Valladolid

2023-11-03

Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012Relapsed/Refractory Multiple Myeloma

Ichnos Sciences SA

Phase 1

200

Salamanca, Badalona, Barcelona, Madrid, Pamplona

2023-11-01

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Valencia

2023-10-31

Recruiting

Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

NCT05762211Transplant Complication

DrugPooled allogeneic fecal microbiotherapy

MaaT Pharma

Phase 2

387

Barcelona, Granada, Madrid, Majadahonda, Murcia, Pamplona, Salamanca, Santander

2023-10-31

Recruiting

Durvalumab and Tremelimumab in Resectable HCC

NCT05440864Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab

University Health Network, Toronto

Phase 2

Pamplona

2023-10-26

Active, closed

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333Congestive Heart Failure

AskBio Inc

Phase 2

150

Barcelona, Pamplona, Madrid, Santiago de Compostela, Valencia

2023-10-20

Active, closed

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Multiple Myeloma

DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan

Celgene

Phase 3

Badalona, L'Hospitalet Del Llobregat, Barcelona, Pamplona, Madrid, Salamanca, Valencia

2023-10-16

Active, closed

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083Multiple Myeloma

DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide

Stichting European Myeloma Network

Phase 3

759

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santiago de Compostela, Seville, Valencia

2023-10-10

Active, closed

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

NCT05888844Cutaneous Squamous Cell Carcinoma

DrugINCB099280

Incyte Corporation

Phase 2

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Seville

2023-10-09

Recruiting

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

NCT06072131Peripheral T Cell Lymphoma

DrugsBelinostat·Pralatrexate·CHOP·Prednisone

Acrotech Biopharma Inc.

Phase 3

504

Bilbao, Moncloa-Aravaca, Pamplona, Barcelona, Madrid, Salamanca, Valencia, Zaragoza

2023-10-04

Recruiting

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT06057402Multiple Myeloma

DrugElranatamab

Pfizer

Phase 4

Pamplona, Valencia

2023-10-03

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386IC-MPGN

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

106

Pamplona, Almería, Barcelona, Madrid, Salamanca

2023-10-02

Recruiting

APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials

NCT06868355Cancer

University of Manchester

Observational

Barcelona, Madrid, Pamplona, Valencia

2023-09-28

Active, closed

RCT to Evaluate STERN FIX Device as a Sternal Stabilization System in Patients After Sternotomy

NCT05953259Median Sternotomy

NEOS Surgery

Not applicable

Barcelona, Pamplona, Madrid, Seville

2023-09-27

Active, closed

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT05822752Hepatocellular Carcinoma

DrugsLivmoniplimab·Budigalimab·Sorafenib·Lenvatinib

AbbVie

Phase 2

130

Santander, Córdoba, Majadahonda, Pamplona, Barcelona, Madrid, Seville, Zaragoza

2023-09-21

Active, closed

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

NCT05849610High-Risk de Novo Multiple Myeloma

DrugsTalquetamab·Teclistamab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Murcia, Pamplona, Salamanca, Santander, Santiago de Compostela

2023-09-21

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Santiago de Compostela, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Seville, Valencia

2023-09-18

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Santander, Santiago de Compostela, Madrid, Majadahonda, Barcelona, Girona, Oviedo, Pamplona

2023-09-14

Recruiting

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938Community-acquired Pneumonia

Biotest

Phase 3

590

Palma de Mallorca, Sabadell, Terrassa, Córdoba, Majadahonda, Pamplona, Oviedo, Barcelona

2023-09-09

By invitation

EFFECT OF A ONLINE NUTRITION EDUCATION PROGRAM IN PRESCHOOLER'S FAMILIES ON THEIR ADHERENCE TO THE MEDITERRANEAN DIET

NCT06828367Prevention of Childhood Obesity, Community Health Education

Fundacion Miguel Servet

Not applicable

160

Pamplona

2023-09-01

Active, closed

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480Biliary Tract Cancer

DrugsAlbumin-Bound Paclitaxel·Teysuno·Durvalumab·Oxaliplatin

AstraZeneca

Phase 3

142

Barcelona, Madrid, Pamplona, Seville

2023-08-16

Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615Hormone-refractory Prostate Cancer

Astellas Pharma Global Development, Inc.

Phase 1

437

Barcelona, Logroño, Madrid, Málaga, Pamplona, Valencia

2023-08-10

Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

NCT05954312Advanced Solid Tumors

DrugsDocetaxel·Paclitaxel·Pembrolizumab

Vividion Therapeutics, Inc.

Phase 1

290

Barcelona, Madrid, Pamplona, Valencia

2023-07-28

Recruiting

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement

DrugFutibatinib

Taiho Oncology, Inc.

Phase 2

120

Barcelona, Madrid, Pamplona

2023-07-05

Active, closed

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT05883644Advanced Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

111

Barcelona, Córdoba, Madrid, Pamplona

2023-06-27

Recruiting

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

NCT05788536Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Regeneron Pharmaceuticals

Phase 1/2

Pamplona, Barcelona, Las Palmas de Gran Canaria, Madrid

2023-06-27

Recruiting

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

NCT05427370Coronary Artery Disease, Heart Failure Systolic

Sunnybrook Health Sciences Centre

Not applicable

754

Barcelona, El Palmar, Alicante, Pamplona

2023-06-22

Active, closed

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Alexion Pharmaceuticals, Inc.

Phase 3

165

A Coruña, Barcelona, Pamplona, Seville

2023-06-07

Active, closed

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

NCT05888831Advanced Solid Tumors

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 1/2

100

Málaga, Badalona, Pamplona, Madrid

2023-06-06

Recruiting

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

NCT06923761Advanced Solid Malignancy

Grey Wolf Therapeutics

Phase 1/2

300

Barcelona, Madrid, Málaga, Pamplona, Valencia

2023-05-21

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

NCT05765812Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III

DrugTemozolomide

Debiopharm International SA

Phase 1/2

116

Barcelona, Donostia / San Sebastian, Madrid, Pamplona, Valencia

2023-05-15

Active, closed

Study of GS-4528 in Adults With Solid Tumors

NCT05840224Solid Tumor

DrugZimberelimab

Gilead Sciences

Phase 1

182

Barcelona, Madrid, Pamplona

2023-05-11

Active, closed

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05789069Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer

DrugTislelizumab

HiFiBiO Therapeutics

Phase 1

Madrid, Pamplona, Valencia

2023-05-09

Recruiting

Digital Transformation of Continuity of Care for Peripherally Inserted Central Catheters: SpadCare Experience

NCT06905119Infusions, Intravenous, Administration, Intravenous, Home Infusion Therapy, Parenteral Nutrition, Home

Fundacion Miguel Servet

Not applicable

201

Pamplona

2023-05-04

Active, closed

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

NCT05876754Cholangiocarcinoma

DrugIvosidenib

Servier Affaires Médicales

Phase 3

299

A Coruña, Barcelona, Córdoba, Elche, Madrid, Pamplona, Santander

2023-05-03

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer

Genentech, Inc.

Phase 1

210

Pamplona, Barcelona, Madrid

2023-05-02

Recruiting

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

NCT05855083Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation

Omeros Corporation

Phase 2

Pamplona

2023-05-01

Recruiting

Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data

NCT05845255Quality of Life, Epilepsy (treatment Refractory)

MJN Neuroserveis, S.L

Observational

130

Barcelona, Madrid, Pamplona

2023-05-01

Active, closed

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

NCT05466799Locally Advanced Pancreatic Cancer

OncoSil Medical Limited

Phase 2

Barcelona, Madrid, Pamplona

2023-04-26

Active, closed

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine

AstraZeneca

Phase 2

294

Barcelona, Madrid, Pamplona

2023-04-24

Active, closed

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591Advanced Non-Small Cell Lung Cancer

DrugsBNT116·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

Badalona, Manresa, Castellon, Madrid, Málaga, Pamplona, Valencia

2023-04-21

Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation

DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel

Institut de Recherches Internationales Servier

Phase 1/2

554

Barcelona, Madrid, Pamplona, Valencia

2023-04-18

Recruiting

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

Weill Medical College of Cornell University

Not applicable

2,300

Elche, Barcelona, Madrid, Pamplona

2023-04-17

Recruiting

Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

NCT05804318Prostate Cancer

Varian, a Siemens Healthineers Company

Not applicable

132

Pamplona

2023-04-13

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia

Schrödinger, Inc.

Phase 1

Barcelona, Madrid, Pamplona, Salamanca

2023-04-10

By invitation

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

NCT05669989Plasma Cell Myeloma

DrugsIsatuximab·Carfilzomib·Cemiplimab·Pomalidomide

Sanofi

Phase 2

Seville, Santander, Badalona, Madrid, Pamplona, Salamanca

2023-04-05

Recruiting

AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)

NCT05890716Cardiomyopathies, Cardiac Arrest, Cardiac Arrhythmias, Sudden Cardiac Death

Idoven 1903 S.L.

Observational

5,342

Barcelona, Ciudad Real, A Coruña, Madrid, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia

2023-04-04

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma

DrugsLifileucel·Pembrolizumab

Iovance Biotherapeutics, Inc.

Phase 3

670

Santander, Málaga, Barcelona, Madrid, Pamplona, Seville, Valencia

2023-03-30

Active, closed

Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

NCT05501873Atrial Fibrillation

Boston Scientific Corporation

Observational

1,173

Madrid, Pamplona, Valencia, Zaragoza

2023-03-24

Active, closed

Air Cold Atmospheric Pressure Plasma Treatment for Acceleration of Venous Ulcer Healing

NCT05894096Venous Leg Ulcer

Clinica Universidad de Navarra, Universidad de Navarra

Not applicable

Alcázar de San Juan, Madrid, Pamplona

2023-03-24

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

NCT05646836Multiple Myeloma

DrugsCevostamab·Tocilizumab

Genentech, Inc.

Phase 1

Pamplona, Valencia

2023-03-21

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

A Coruña, L'Hospitalet de Llobregat, Córdoba, Málaga, Pamplona, Barcelona, Girona, Madrid

2023-03-15

Active, closed

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

NCT05662397Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer

DrugCemiplimab

HotSpot Therapeutics, Inc

Phase 1/2

Barcelona, Madrid, Pamplona

2023-03-15

By invitation

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05735483Atopic Dermatitis, Eczema

DrugLebrikizumab

Eli Lilly and Company

Phase 3

333

Esplugues de Llobregat, Las, Madrid, Pozuelo de Alarcón, Pamplona, Pontevedra, Manises

2023-03-09

Active, closed

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

NCT05639114Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

436

Santiago Compostela, Elche, Badalona, Santander, Barcelona, San Sebastian Reyes, Pamplona, Vigo

2023-03-02

Recruiting

High Definition Medicine for Solid Tumors Oncology

NCT06590506Metastatic Solid Tumor, Advanced Cancer

Centro Nacional de Investigaciones Oncologicas CARLOS III

Observational

300

A Coruña, Fuenlabrada, Palma de Mallorca, Pamplona, Seville, Barcelona, Cáceres, Madrid

2023-03-02

Recruiting

Effect of Strength-resistance Exercise in the Reduction of Gestational Diabetes in Pregnant Women with Overweight or Obesity

NCT05840497Diabetes, Gestational

Fundacion Miguel Servet

Not applicable

200

Pamplona

2023-03-01

Active, closed

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

NCT05548127Breast Cancer

DrugsVepdegestrant·Abemaciclib

Pfizer

Phase 1/2

Barcelona, Madrid, Pamplona, Seville

2023-02-23

Recruiting

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

NCT05651932Multiple Myeloma, Myeloma, Myeloma Multiple

DrugsMezigdomide·Carfilzomib·Pomalidomide·Dexamethasone

K36 Therapeutics, Inc.

Phase 1

165

Pamplona, Barcelona, Madrid, Salamanca

2023-02-22

Recruiting

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

NCT05683418HR+/HER2-negative Breast Cancer

DrugsRibociclib·Palbociclib·Fulvestrant

Totus Medicines

Phase 1

241

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Valencia

2023-02-15

Recruiting

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

NCT05682378Heterozygous or Homozygous Familial Hypercholesterolemia

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

195

Pamplona, Oviedo, A Coruña, Córdoba

2023-02-10

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Badalona, Barcelona, L'Hospitalet de Llobregat, Córdoba, Madrid, El Palmar, Pamplona, Valencia

2023-02-08

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Valencia

2023-01-23

Recruiting

Novel Medical Device for Pharmacological Therapy

NCT06938750Vascular Access, Vascular Access Complication, Vascular Access Complications, Catheter Malfunction

Fundacion Miguel Servet

Not applicable

262

Pamplona

2023-01-20

Active, closed

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526Alzheimer Disease

AriBio Co., Ltd.

Phase 3

1,535

Barcelona, Huelva, Madrid, Pamplona, Salamanca, San Sebastián, Seville, Valencia

2022-12-23

Active, closed

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

NCT05527340Multiple Myeloma

DrugsIberdomide·Daratumumab·Dexamethasone

PETHEMA Foundation

Phase 2

140

Madrid, Palma de Mallorca, Pamplona, Salamanca, San Cristóbal de La Laguna, Santander, Seville, Valencia

2022-12-15

Active, closed

A Study of Daratumumab

NCT05438043Multiple Myeloma

DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

213

Alcorcón, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Pozuelo de Alarcón

2022-12-15

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Barcelona, Madrid, Majadahonda, Málaga, Ourense, Palma de Mallorca, Pamplona, Santander

2022-12-13

Active, closed

Exercise Effects on Health Status in Patients With Severe Mental Illness

NCT05834309Exercise, Metabolic Syndrome, Mental Disorders, Severe, Severe Mental Disorder

Universidad Pública de Navarra

Not applicable

100

Pamplona

2022-12-05

Active, closed

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

NCT05608044Metastatic Colorectal Cancer

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

234

Barcelona, Madrid, Pamplona, Santander

2022-11-30

Active, closed

Multiparametric MRI in Healthy Volunteers and CKD Patients

NCT05229263Chronic Kidney Diseases, Healthy

Mario Negri Institute for Pharmacological Research

Not applicable

140

Pamplona

2022-11-25

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis

DrugRamantamig

Janssen Research & Development, LLC

Phase 1

180

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2022-11-22

Active, closed

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT05583227Eosinophilic Esophagitis

DrugTezepelumab

AstraZeneca

Phase 3

368

Barcelona, Madrid, Pamplona, Seville, Tomelloso

2022-11-10

Recruiting

NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

NCT05558319Newly Diagnosed Multiple Myeloma

DrugsIberdomide·Isatuximab·Bortezomib·Lenalidomide

PETHEMA Foundation

Phase 3

480

Alcalá de Henares, Pozuelo de Alarcón, Pamplona, Albacete, Badalona, Barcelona, Bilbao, Burgos

2022-11-10

Active, closed

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

NCT05374291Kidney Disease, Chronic, Renal Transplant Failure, Heart Failure, Kidney Failure

DrugDapagliflozin

University Medical Center Groningen

Phase 3

1,750

Barcelona, Lleida, Madrid, Palma de Mallorca, Pamplona, Valencia

2022-11-08

Recruiting

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

NCT06465433Hematologic Malignancies

DrugTafasitamab

Incyte Corporation

Phase 2

Pamplona

2022-11-08

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

284

Pamplona, Barcelona, Madrid

2022-11-04

Recruiting

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

NCT05607420B-cell Non-Hodgkin Lymphoma (B-NHL)

DrugAlemtuzumab

Cellectis S.A.

Phase 1/2

Pamplona, Seville

2022-11-01

Active, closed

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

3,400

Pamplona, Barcelona, Castilleja de la Cuesta, León, Madrid, Seville

2022-11-01

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839Relapsed/Refractory Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Lenalidomide

AbbVie

Phase 1

283

L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Seville

2022-10-20

Recruiting

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

NCT05547321Advanced Solid Tumor

DrugsOMTX705·Tislelizumab·Pembrolizumab

Oncomatryx Biopharma S.L.

Phase 1

150

Barcelona, L'Hospitalet de Llobregat, Santiago de Compostela, San Sebastián, Madrid, Pamplona

2022-10-20

Active, closed

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359Atopic Dermatitis, Eczema

DrugLebrikizumab

Eli Lilly and Company

Phase 3

377

Esplugues de Llobregat, Las, Madrid, Pamplona

2022-10-18

Active, closed

Optilume Registry for Treatment of Stricture of the Anterior Urethra

NCT05479422Anterior Urethral Stricture, Male

European Association of Urology Research Foundation

Observational

150

Santander, Madrid, Pamplona

2022-10-13

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Badalona, Barcelona, El Palmar, Jerez de la Frontera, León, Madrid, Málaga, Pamplona

2022-10-13

Active, closed

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740Advanced Solid Tumors

DrugPembrolizumab

Bayer

Phase 1

129

Pamplona, Barcelona, Madrid

2022-10-11

Active, closed

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903Leukemia, Myeloid, Acute

DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine

Janssen Research & Development, LLC

Phase 1

196

Barcelona, Madrid, Pamplona

2022-10-04

Active, closed

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

DrugsMIRV·Mirvetuximab Soravtansine·Carboplatin

AbbVie

Phase 2

125

A Coruña, Badalona, Córdoba, Pamplona, Badajoz, Barcelona, Lleida, Madrid

2022-09-28

Active, closed

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Badalona, L'Hospitalet de Llobregat, Santander, Córdoba, Pamplona, Barcelona, Cáceres, Madrid

2022-09-20

Active, closed

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor

DrugElironrasib

Revolution Medicines, Inc.

Phase 1

222

Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Seville, Zaragoza

2022-09-19

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Barcelona, Madrid, Pamplona, Pontevedra, Sabadell, Santander, Torrejón de Ardoz, Vigo

2022-09-19

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville

2022-09-06

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

Córdoba, Madrid, El Palmar, Barcelona, Pamplona, Santiago de Compostela, Valencia

2022-08-31

Active, closed

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer

DrugsPemetrexed·Carboplatin

iTeos Therapeutics

Phase 2

Palma de Mallorca, Pamplona, Valencia, A Coruña, Badajoz, Barcelona, Manresa, Ourense

2022-08-26

Active, closed

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

Biogen

Phase 2

416

Pamplona, Getxo, Barcelona, Córdoba, Lleida, Seville, Valencia

2022-08-24

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Badalona, Bilbao, Las Palmas de Gran Canaria, Pamplona, Pontevedra, Vigo, Seville, Burjassot

2022-08-22

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054Multiple Myeloma

DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab

Regeneron Pharmaceuticals

Phase 1

317

Santiago de Compostela, Badalona, Santander, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Salamanca

2022-08-17

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Barcelona, Madrid, Málaga, Pamplona, Pozuelo de Alarcón

2022-08-11

Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

DrugsAbraxane·Nab-paclitaxel·Gemcitabine

Panbela Therapeutics, Inc.

Phase 2/3

600

Badalona, Santander, Jaén, Barcelona, Madrid, El Palmar, Pamplona, Barakaldo

2022-08-08

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

DrugsPirtobrutinib·Ibrutinib

Loxo Oncology, Inc.

Phase 3

737

Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Marbella, Pamplona, Santander, Seville

2022-07-22

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Madrid, Pamplona, Pontevedra, Sabadell, Santander, Torrejón de Ardoz

2022-07-22

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

DrugsZilovertamab vedotin·Nemtabrutinib

Merck Sharp & Dohme LLC

Phase 2

189

L'Hospitalet Del Llobregat, Barcelona, Madrid, Pamplona, Salamanca

2022-07-21

Recruiting

Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS

NCT05451784Metastatic Triple-Negative Breast Carcinoma

DrugSerplulimab

Fundacio Clinic Barcelona

Phase 1/2

Barcelona, Madrid, Pamplona

2022-07-20

Active, closed

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

NCT05126277Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

452

Santiago Compostela, Pamplona, Vigo, San Cristóbal de La Laguna, Valencia, Barcelona, Madrid

2022-07-14

Active, closed

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934Eosinophilic Granulomatosis With Polyangiitis

DrugsDepemokimab·Mepolizumab

GlaxoSmithKline

Phase 3

163

Barcelona, Granada, Pamplona, Zaragoza

2022-07-14

By invitation

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

NCT05481827Age Related Macular Degeneration (AMD)

Gyroscope Therapeutics Limited

Phase 2

225

Barcelona, Madrid, Pamplona

2022-07-12

Active, closed

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997Multiple Myeloma

DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone

Celgene

Phase 3

939

Pamplona, Barcelona, Cáceres, Córdoba, Madrid, Málaga, Murcia, Oviedo

2022-06-23

Active, closed

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

NCT05405166Plasma Cell Myeloma Recurrent

DrugsParacetamol / Acetaminophen·Montelukast·Diphenhydramine·Isatuximab

Sanofi

Phase 3

531

Murcia, Badalona, Santander, Pamplona, Madrid, Salamanca

2022-06-23

Active, closed

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

NCT05382052Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment

Fundación GECP

Observational

100

A Coruña, Alicante, Badalona, Barcelona, Bilbao, Córdoba, Girona, Pamplona

2022-06-17

Active, closed

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075Non-Small Cell Lung Cancer

DrugsOpnurasib·Docetaxel

Novartis Pharmaceuticals

Phase 3

Pamplona, Oviedo, Córdoba, Madrid

2022-06-15

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Badalona, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia

2022-06-14

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsNanoparticle Albumin-Bound Paclitaxel·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Inc

Phase 1

681

Pamplona, A Coruña, Barcelona, Madrid, Málaga, Seville, Valencia

2022-06-08

Recruiting

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05211570Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia

DrugVenetoclax

AB Science

Phase 1/2

Alicante, Cáceres, Madrid, Pamplona, Seville

2022-06-01

Active, closed

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974Non-small Cell Lung Cancer

DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin

Gilead Sciences

Phase 2

193

A Coruña, Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Rincón de la Victoria, Santiago de Compostela

2022-05-30

Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

NCT05434234Advanced Solid Tumor

DrugTam-Peli

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

312

Barcelona, Leganés, Madrid, Moncloa-Aravaca, Pozuelo de Alarcón, Usera, Pamplona, Valencia

2022-05-25

Active, closed

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT05338775Relapsed/ Refractory Multiple Myeloma

DrugsTalquetamab·Teclistamab

Janssen Research & Development, LLC

Phase 1

Badalona, Madrid, Pamplona, Salamanca

2022-05-25

Recruiting

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

NCT05416307Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

DrugELA026

Electra Therapeutics Inc.

Phase 2/3

156

Madrid, Pamplona, Seville, Valencia

2022-05-19

Active, closed

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254Metastatic Melanoma, Unresectable Melanoma

DrugsIO102-IO103·Pembrolizumab

IO Biotech

Phase 3

407

Seville, A Coruña, Barcelona, Madrid, Málaga, Oviedo, Pamplona, Valencia

2022-05-17

Recruiting

First in Human Study of T3P-Y058-739 (T3P)

NCT05120596Advanced Solid Tumor

DrugPembrolizumab

T3 Pharmaceuticals AG

Phase 1/2

100

Pamplona, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2022-04-26

Active, closed

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

NCT05028348Multiple Myeloma

DrugsElotuzumab·Selinexor·Pomalidomide·Dexamethasone

European Myeloma Network B.V.

Phase 3

117

Barcelona, Gijón, Girona, Madrid, Murcia, Pamplona, Salamanca, Santander

2022-04-19

Recruiting

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

NCT04685616Hodgkin Lymphoma

DrugsVinblastine·Filgrastim·Pegfilgrastim·Bleomycin

University College, London

Phase 3

1,042

Barcelona, Pamplona

2022-04-14

Recruiting

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

NCT05356741Locally Advanced or Metastatic HER2-Expressing Cancers

DrugsKeytruda·Pembrolizumab

Vir Biotechnology, Inc.

Phase 1/2

645

Madrid, Barcelona, Pamplona, Pozuelo de Alarcón

2022-04-13

Recruiting

OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

NCT04493632Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms

OncoSil Medical Limited

Observational

500

Las Palmas de Gran Canaria, Madrid, Pamplona, Valladolid

2022-04-12

Active, closed

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD

MaaT Pharma

Phase 3

Barcelona, El Palmar, Granada, Madrid, Murcia, Pamplona, Salamanca, Santander

2022-03-25

Active, closed

Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients

NCT05193019Ischemic Heart Disease, Acute Coronary Syndrome

Fundación EPIC

Observational

717

L'Hospitalet de Llobregat, Barakaldo, Galdakao, Gijón, León, Madrid, Pamplona, Salamanca

2022-03-14

Active, closed

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567Breast Neoplasm, Neoplasm Metastasis

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

368

A Coruña, Palma, Barcelona, El Palmar, Málaga, Pamplona, Reus, Valencia

2022-03-11

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781Multiple Myeloma

DrugCilta-cel

Janssen Research & Development, LLC

Phase 4

295

Pamplona, Salamanca

2022-03-09

Active, closed

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

NCT05250973Amyloidosis

DrugsBortezomib·Daratumumab·Dexamethasone·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

151

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2022-03-01

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

L'Hospitalet de Llobregat, A Coruña, Madrid, Pamplona, Valencia, Barcelona, Seville

2022-02-03

By invitation

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

300

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid

2022-02-03

Recruiting

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC

DrugsPembrolizumab KEYTRUDA·Pemetrexed·Carboplatin

Synthekine

Phase 1/2

364

Barcelona, Logroño, Madrid, Málaga, Pamplona

2022-01-25

Active, closed

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer

DrugsTrastuzumab emtansine·Trastuzumab·Pembrolizumab

Ascendis Pharma Oncology Division A/S

Phase 1/2

320

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Oviedo, Pamplona, Seville

2022-01-11

Active, closed

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

NCT05060627Relapsed Multiple Myeloma

DrugsBelantamab mafodotin·Carfilzomib·Dexamethasone

PETHEMA Foundation

Phase 1/2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Oviedo, Palma de Mallorca, Pamplona

2021-12-20

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Seville, Valencia

2021-12-14

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Barakaldo, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Pamplona

2021-12-10

Active, closed

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969Locally Advanced or Metastatic Solid Tumours

DrugsAZD0171·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 2

126

Badalona, Barcelona, Madrid, Majadahonda, Pamplona

2021-12-10

Recruiting

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

350

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Seville, Terrassa, Valencia, Valladolid

2021-12-07

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Sabadell, Pamplona, Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga

2021-12-02

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584Relapsed/Refractory Multiple Myeloma

Janssen Pharmaceutica N.V., Belgium

Observational

300

Barcelona, Gijón, Granada, Jerez de la Frontera, León, Madrid, Palma, Pamplona

2021-11-18

Active, closed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

776

A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pamplona, Seville

2021-11-17

Active, closed

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05117476Advanced Solid Tumor, NSCLC

DrugsCLN-619·Carboplatin (AUC 6)·Dato-DXd·Pemetrexed

Cullinan Therapeutics Inc.

Phase 1

440

Las Palmas de Gran Canaria, Barcelona, Madrid, Pamplona, Sabadell

2021-10-29

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Seville

2021-10-28

Active, closed

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

NCT04988386Amyloid Cardiomyopathy, Transthyretin-Related

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

389

Palma de Mallorca, Santiago de Compostela, Madrid, Majadahonda, Pamplona, Valencia

2021-10-27

Active, closed

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239Neoplasms

DrugsEzabenlimab·Pembrolizumab

Boehringer Ingelheim

Phase 1

151

Badalona, Barcelona, Madrid, Pamplona

2021-10-18

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer

DrugsPalacaparib·Saruparib·Rilvegostomig

AstraZeneca

Phase 1/2

460

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2021-10-18

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Barcelona, Gijón, Las Palmas de Gran Canaria, Madrid, Palma, Pamplona, Pozuelo de Alarcón, Salamanca

2021-10-14

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

Santiago de Compostela, Badalona, Alcorcón, Pamplona, Barcelona, Jaén, Madrid, Seville

2021-10-13

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Granada, El Palmar, Pamplona, Barcelona, Madrid

2021-10-06

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Santiago de Compostela, L'Hospitalet Del Llobregat, Terrassa, Santander, Pamplona, Toledo, Barcelona, Girona

2021-10-04

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462Primary IgA Nephropathy

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

540

Pamplona, Barcelona, Salamanca

2021-09-20

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca, Santander, Seville

2021-08-19

Active, closed

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

NCT05007782Advanced Solid Tumor

DrugsDenikitug·Zimberelimab

Gilead Sciences

Phase 1

304

Barcelona, Madrid, Pamplona

2021-08-18

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

NCT04844866Diffuse Large B-cell Lymphoma

Miltenyi Biomedicine GmbH

Phase 2

213

Barcelona, Madrid, Murcia, Pamplona, Salamanca

2021-08-18

Active, closed

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709Muscle Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

712

Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Pamplona, Seville

2021-08-05

Active, closed

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

NCT04657289Neovascular Age-related Macular Degeneration (nAMD)

DrugRanibizumab

Hoffmann-La Roche

Phase 3

451

L'Hospitalet de Llobregat, San Cugat Del Valles, Majadahonda, Pamplona, Oviedo, Barcelona, Córdoba, Madrid

2021-07-14

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

NCT04669171Follicular Lymphoma, Marginal Zone Lymphoma

DrugsLenalidomide·Rituximab

Enterome

Phase 1/2

Barcelona, Madrid, Pamplona, Salamanca

2021-07-05

Active, closed

Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease

NCT04595266Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer

DrugsFolfox·Bevacizumab

Grupo Espanol Multidisciplinario del Cancer Digestivo

Phase 2

Barcelona, Sabadell, Madrid, Pamplona, Valencia

2021-06-29

Active, closed

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722Colorectal Cancer

DrugsPembrolizumab/Vibostolimab·MK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab

Merck Sharp & Dohme LLC

Phase 2

302

Santander, Barcelona, Madrid, Málaga, Pamplona, Oviedo, Valencia

2021-06-25

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

A Coruña, Badalona, Barcelona, Córdoba, LHospitalet de Llobregat, Madrid, Pamplona, Sabadell

2021-06-24

Active, closed

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

469

Santiago Compostela, L'Hospitalet de Llobregat, El Palmar, Pamplona, Valencia, Barcelona, Madrid, Málaga

2021-06-15

Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer

DrugsImzokitug·Pumitamig·Docetaxel·Nivolumab

Bristol-Myers Squibb

Phase 1/2

1,109

Málaga, Badalona, Barcelona, Madrid, Pamplona

2021-05-27

Active, closed

Multicenter Clinical Trial Comparing Treatment with Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control with Hyaluronic Acid in Patients with Knee Osteoarthritis.

NCT05086939Knee Osteoarthritis

DrugHyaluronic Acid

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

Phase 3

124

Barcelona, Madrid, Málaga, Murcia, Pamplona, Salamanca

2021-05-26

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Barcelona, Madrid, Pamplona, Santiago de Compostela, Valencia

2021-05-21

Recruiting

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560Acute Leukemia

DrugBleximenib

Janssen Research & Development, LLC

Phase 1/2

420

Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2021-05-19

Active, closed

Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)

NCT04728295Parkinson Disease

InSightec

Not applicable

Madrid, Pamplona

2021-05-14

Active, closed

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622Prostate Cancer

DrugsTalazoparib·Enzalutamide

Pfizer

Phase 3

599

Elche, Badalona, L'Hospitalet de Llobregat, Manresa, Lugo, Majadahonda, Pamplona, Oviedo

2021-05-12

Active, closed

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092Diffuse Large B-cell Lymphoma

DrugsTafasitamab·Vincristine·Doxorubicin·Prednisone

Incyte Corporation

Phase 3

899

Badalona, Barcelona, Girona, Jerez de la Frontera, Lugo, Madrid, Pamplona, Salamanca

2021-05-11

Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177

NCT04949282Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

DrugsLutetium [177Lu] oxodotreotide/dotatate·Lutathera

Sociedad Española de Medicina Nuclear e Imagen Molecular

Observational

5,000

Santiago de Compostela, Granada, Palma de Mallorca, L'Hospitalet de Llobregat, Getafe, Majadahonda, El Palmar, Pamplona

2021-05-10

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 3

893

Barcelona, Granada, Lleida, Madrid, Málaga, Pamplona, Santiago de Compostela

2021-05-10

Active, closed

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

NCT04675333Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

DrugsEvorpacept·Cisplatin/Carboplatin·Fluorouracil·Keytruda

ALX Oncology Inc.

Phase 2

172

Barcelona, Badalona, L'Hospitalet de Llobregat, Leganés, Madrid, Málaga, Pamplona

2021-05-10

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103Metastatic Non Small Cell Lung Cancer

DrugLifileucel

Iovance Biotherapeutics, Inc.

Phase 2

170

A Coruña, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Salamanca, Seville

2021-05-07

Active, closed

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

NCT04777331Parkinsons Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 2

586

Elche, Sant Cugat del Vallès, Donosti-San Sebastián, A Coruña, Alcorcón, Móstoles, Pozuelo de Alarcón, Pamplona

2021-05-05

Active, closed

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

NCT04868877Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

DrugsBispecific·Tagrisso·Osimertinib

Merus B.V.

Phase 1/2

194

Barcelona, Madrid, Pamplona, Valencia

2021-04-28

Active, closed

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255Lymphoma, Mantle-Cell

DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib

Loxo Oncology, Inc.

Phase 3

500

Málaga, Barcelona, L'Hospitalet de Llobregat, Pamplona, Palma de Mallorca, Madrid, Valencia

2021-04-08

Active, closed

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

NCT04675294Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

DrugsEvorpacept·Keytruda·Pembrolizumab

ALX Oncology Inc.

Phase 2

189

Barcelona, Madrid, Málaga, Pamplona

2021-04-02

Active, closed

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

DrugsAdagrasib·Taxotere·Docetaxel

Mirati Therapeutics Inc.

Phase 3

453

Pamplona, A Coruña, Alicante, Badalona, Barakaldo, Barcelona, Córdoba, Girona

2021-02-23

Active, closed

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

NCT04657081Acute Myeloid Leukemia

DrugsDecitabine·Venclexta·Venetoclax

Taiho Oncology, Inc.

Phase 1/2

101

Oviedo, L'Hospitalet de Llobregat, Pamplona, Madrid, Salamanca, Valencia

2021-02-09

Active, closed

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

NCT04229979Acute Myeloid Leukemia

DrugsGm-Csf·Sargramostim·Ara-C·Decitabine

Sellas Life Sciences Group

Phase 3

127

Cáceres, Córdoba, Madrid, Oviedo, Pamplona, Salamanca, Seville, Valencia

2021-02-08

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552Hematological Malignancies

DrugTalquetamab

Janssen Research & Development, LLC

Phase 2

510

Badalona, Barcelona, Madrid, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2021-02-01

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Barcelona, Jaén, Lleida, Madrid, Málaga, Pamplona, Santander, Seville

2021-01-28

Active, closed

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia

DrugBlinatumomab

Amgen

Phase 1/2

181

Seville, Santander, Salamanca, Badalona, Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat, Pamplona

2021-01-04

Recruiting

Persistent COVID-19 Registry in Navarre.

NCT07417176Long COVID Symptoms, Long COVI

Fundacion Miguel Servet

Observational

200

Pamplona

2021-01-04

Active, closed

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 2

102

Barcelona, Madrid, Pamplona, Seville

2020-12-30

Active, closed

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04586426Multiple Myeloma

DrugsTalquetamab·Teclistamab

Janssen Research & Development, LLC

Phase 1/2

228

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Salamanca, Santander

2020-12-15

Recruiting

FS222 First in Human Study in Patients With Advanced Malignancies

NCT04740424Advanced Cancer, Metastatic Cancer

invoX Pharma Limited

Phase 1

260

Pamplona, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Seville, Valencia

2020-12-14

Active, closed

First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)

NCT04725474Solid Tumor, Adult

DrugsVisugromab·Visugromab RDE·Nivolumab

CatalYm GmbH

Phase 1/2

199

Barcelona, Madrid, Pamplona

2020-12-09

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

DrugsAdagrasib·Pembrolizumab

Mirati Therapeutics Inc.

Phase 2/3

626

Pamplona, A Coruña, Badalona, Barcelona, Bilbao, Burgos, Jerez de la Frontera, Las Palmas de Gran Canaria

2020-12-02

Active, closed

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

NCT04127110Non Small Cell Lung Cancer

DrugLorlatinib

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

L'Hospitalet de Llobregat, Barcelona, Madrid, Palma de Mallorca, Pamplona, Seville

2020-11-17

Active, closed

A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

NCT04658199Progressive Supranuclear Palsy

UCB Biopharma SRL

Phase 1

Barcelona, Madrid, Pamplona

2020-11-16

Active, closed

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059Prostatic Neoplasms

DrugsLhrha·Apalutamide

Janssen Pharmaceutica N.V., Belgium

Phase 3

691

Cadiz, Ferrol, Jerez de la Frontera, Madrid, Málaga, Pamplona, Seville, Valencia

2020-11-12

Active, closed

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235AL Amyloidosis

DrugsAnselamimab·Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)

Alexion Pharmaceuticals, Inc.

Phase 3

281

Barcelona, Gijón, Granada, Madrid, Majadahonda, Pamplona, Salamanca, Seville

2020-11-03

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Barcelona, Córdoba, Madrid, Pamplona, Santander, Zaragoza

2020-10-19

Active, closed

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664Carcinoma, Non-Small-Cell Lung

DrugsAmivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

308

A Coruña, Badalona, Barcelona, Burgos, Madrid, Majadahonda, Málaga, Pamplona

2020-10-13

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Alcalá de Henares, Badalona, Barcelona, Gijón, L'Hospitalet de Llobregat, Madrid, Palma, Pamplona

2020-10-08

Active, closed

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

NCT04483739Multiple Myeloma

European Myeloma Network B.V.

Phase 3

302

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander

2020-09-25

Active, closed

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098Hematological Malignancies

DrugTeclistamab

Janssen Research & Development, LLC

Phase 2

194

Badalona, Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2020-09-17

Active, closed

Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

NCT04565054Breast Cancer Female

DrugAbemaciclib

Women's Cancer Study Group GmbH

Phase 3

1,260

Palma, Barcelona, Cáceres, Elche, Madrid, Manresa, Málaga, Pamplona

2020-09-02

Active, closed

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825AL Amyloidosis

DrugsAnselamimab·Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)

Alexion Pharmaceuticals, Inc.

Phase 3

125

Barcelona, Gijón, Majadahonda, Pamplona, Seville

2020-08-25

Active, closed

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283Diffuse Large B-cell Lymphoma

DrugsBrentuximab Vedotin·Lenalidomide·Rituximab

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

239

L'Hospitalet de Llobregat, Cáceres, Pozuelo de Alarcón, Marbella, Pamplona, Barcelona, Madrid, Pozuelo de Alarcon (madrid)

2020-08-20

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/pamplona

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 612 of those studies with a site in Pamplona.

How many clinical trials are recruiting in Pamplona?

294 of the 612 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 21 have not yet opened recruitment, 281 are active but closed to new participants, and 16 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Pamplona), 612 studies
Phase	Studies	Recruiting	Share
Phase 3	209	80	34.2%
Phase 2	116	37	19%
Phase 1/2	81	58	13.2%
Phase 1	75	38	12.3%
Not applicable	56	32	9.2%
Observational	46	29	7.5%
Phase 2/3	23	15	3.8%
Phase 4	6	5	1%

Most active sponsors

Lead sponsors with the most studies (Pamplona)
Lead sponsor	Studies	Recruiting
Janssen Research & Development, LLC	44	15
AstraZeneca	41	20
Novartis Pharmaceuticals	22	10
AbbVie	20	8
Fundacion Miguel Servet	18	15
Clinica Universidad de Navarra, Universidad de Navarra	16	10
Bristol-Myers Squibb	15	11
Hoffmann-La Roche	15	6
Regeneron Pharmaceuticals	15	9
Sanofi	11	3

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.